Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by SanFrancisco99on Jul 07, 2014 11:52pm
165 Views
Post# 22723602

RE:RE:Seeking Answers

RE:RE:Seeking Answers

That's right and a good point, Ledrog.  I realize Seeking Alpha is a website and for those that don't realize that, your message will help them decipher what I mean.  I'm glad that you understand that basic point.

To be clear (and as you have pointed out):  My comments/questions are in fact focused upon that particular author and not upon the SA website in general.

I'd like to understand the statement I highlighted from the recent SA article - and what his source is on that in terms of supporting his statement.  To the two potential sources I mentioned (management OR a false assumption on the writer's part) I could add a third:  He might have made a independent survey of all possible pharmas who might have made a deal with pharma and from that data determined that a deal was not a possibility.

 

If he did do that huge amount of research for his article and that one statement, then I applaud that.  But I'm being funny here, as it would be too much research to expect for a one-line statement.

Thus, the source would be either RVX management or a false assumption.  I think it is more likely the latter and not the former.  I'd like to hear his comment on this.

 

Bullboard Posts